aidot

[View original text]

As medical artificial intelligence (AI) technology drew attention due to COVID-19, latecomers entered and stood out, entering the second round of competition in the medical AI 

solution market.

On 6th of July, according to related industries, In the early days, the medical AI solution market was centered on representative companies such as Lunit, Vuno, and JLK. However, 

recently, new companies have released AI medical solutions in various fields such as cervical cancer and stroke and exported them overseas, making progress one after another.

These companies plan to dominate the market in a way that is differentiated from existing companies, such as applying AI diagnosis technology using pathological tissue or using 

unsupervised learning. According to the Small and Medium Business Technology Information Promotion Agency, the global smart healthcare market is expected to grow at an 

average annual rate of more than 20% from about $ 96 billion in 2016 to about $ 206 billion in 2020.

Medical AI platform company doAI provides AI diagnostic solutions based mainly on imaging, whereas medical AI companies provide AI diagnostic solutions, they have developed a medical AI solution for microscopic reading of pathological tissue.  Prior to the release of the product, it has recently been introduced to Cambodia, receiving a lot of attention.

With the support of the Korea International Cooperation Agency (KOICA), doAI has completed the development of an AI automatic reading system that analyzes cervical cancer 

through a mobile device app on images obtained by examining cell slides, and has applied for three related patents in Korea and the United States. In addition, in collaboration with 

the GC Green Cross Medical Foundation, it is developing a “chromosome sorting and reading artificial intelligence solution” that analyzes chromosome images in the mid-phase of 

cell division to determine the number and structural abnormality of chromosomes. In particular, the cervical cancer AI reading technology was approved by the Cambodian Ministry of 

Health and recently conducted remote video training for Cambodian medical staff.

An official from doAI said, "Cambodia has very few single-digit pathologists and is culturally unfamiliar with women getting tested, so it is in high demand, and AI cervical cancer 

reading solutions are mainly targeted in developing countries with poor medical care, and plans to start full-scale operations in ASEAN."

The company was co-founded by CEO Yong-joon Choi and Shin-ho Do, a professor at Harvard Medical School, who is well-known in the field of AI medical devices. The company is 

establishing partnerships with leading hospitals in Korea such as Seoul National University Hospital, Asan Hospital, Yonsei University Severance Hospital, Seoul and 

Yeouido St. Mary's Hospital, Chung-Ang University Hospital, and Ewha Womans University Hospital.

Another company AIDOT (formerly Buzzpole), an AI medical information and communication technology (ICT) company, developed an AI cervical cancer remote reading system called "Serbiray AI" and exported it overseas. It also developed AI portable carotid artery ultrasound equipment that can pre-screen the risk of stroke and received formal approval for 

"Multi-Institutional Multi-Clinical Test (CRIS)."  In recognition of its technological prowess, the company was finally selected as the "300 Promising Companies in Seoul" in 2020 

promoted by the Seoul Metropolitan Government and Invest Seoul Center.

In March, the company signed a contract to exclusively supply the cervical cancer reading solution to Genius, a Swedish company that produces colposcope cameras. In addition, 

after recently signing a business cooperation contract with Snet System's Chinese subsidiary to conduct business in China, it also signed an initial system export contract worth 

about 100,000 dollars, mainly in Beijing and others.

AIDOT also expects to achieve export performance of 4 billion won (4 million dollars) this year by supplying 'Cerviray AI' to Southeast Asia this year.

The last one, Promedius, an AI medical solution developer, which is a company spun off from the Medical Image Intelligence Realization Lab at Asan Medical Center in Seoul, plans to develop a solution for diagnosing abnormal areas in brain CT and introduce a prototype.

The company explained that "Most traditional medical AI solutions utilize supervised learning that learns both data and answers at the same time to respond to rare diseases that 

make it difficult to obtain data. On the other hand, we can overcome the limitations of existing AI models because we utilize next-generation unsupervised learning-based AI."

Promedius was recently selected for the '2020 Early Startup Package', which receives up to 100 million won from the Ministry of Small and Medium Venture Business, and was also 

selected for the 7th 'Startup Nest' program, in which CNT Tech participates as an accelerator.

The solution being developed by the company is expected to be used for classification of emergency patients in hospitals, as it can determine whether various brain lesions are 

abnormal in advance. Promedius also aims to provide customized medical AI software that can be applied to various medical sites such as chest X-ray imaging.

06th. Jul. 2020. 14:12:55 / Metro News / Correspondent Yun-jeong Chae echo@metroseoul.co.kr